Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lecia Vandam Sequist, M.D.

Co-Author

This page shows the publications co-authored by Lecia Sequist and Zofia Piotrowska.
Connection Strength

10.878
  1. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 10 01; 29(10):2092-2097.
    View in: PubMed
    Score: 0.781
  2. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.780
  3. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.770
  4. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
    View in: PubMed
    Score: 0.708
  5. Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2017 03; 12(3):419-421.
    View in: PubMed
    Score: 0.700
  6. Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review. JAMA Oncol. 2016 Jul 01; 2(7):948-54.
    View in: PubMed
    Score: 0.668
  7. Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. J Thorac Oncol. 2016 08; 11(8):e95-e97.
    View in: PubMed
    Score: 0.658
  8. Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand? Oncologist. 2015 Nov; 20(11):1230-2.
    View in: PubMed
    Score: 0.637
  9. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options. Cancer J. 2015 Sep-Oct; 21(5):371-7.
    View in: PubMed
    Score: 0.631
  10. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015 Jul; 5(7):713-22.
    View in: PubMed
    Score: 0.616
  11. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discov. 2021 09; 11(9):2145-2157.
    View in: PubMed
    Score: 0.237
  12. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. J Clin Oncol. 2020 Jun 18; JCO1903123.
    View in: PubMed
    Score: 0.220
  13. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. J Thorac Oncol. 2019 10; 14(10):e226-e228.
    View in: PubMed
    Score: 0.209
  14. Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2019 Sep 13; 11(9).
    View in: PubMed
    Score: 0.209
  15. Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. Oncologist. 2019 12; 24(12):1570-1576.
    View in: PubMed
    Score: 0.204
  16. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
    View in: PubMed
    Score: 0.198
  17. Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma. J Thorac Oncol. 2018 10; 13(10):e204-e206.
    View in: PubMed
    Score: 0.195
  18. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist. 2018 09; 23(9):1054-1062.
    View in: PubMed
    Score: 0.190
  19. Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.183
  20. Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma. J Clin Oncol. 2017 09 10; 35(26):2987-2988.
    View in: PubMed
    Score: 0.179
  21. The Role of Liquid Biopsies in Lung Cancer Screening. Semin Roentgenol. 2017 Jul; 52(3):185-187.
    View in: PubMed
    Score: 0.178
  22. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol. 2016 Apr; 2(4):541-3.
    View in: PubMed
    Score: 0.164
  23. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy. J Thorac Oncol. 2015 Nov; 10(11):1601-7.
    View in: PubMed
    Score: 0.160
  24. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9.
    View in: PubMed
    Score: 0.154
  25. Retrospective chart review of end-of-life (EOL) care in patients with metastatic lung cancer harboring EGFR mutations. J Clin Oncol. 2014 Nov; 32(31_suppl):126.
    View in: PubMed
    Score: 0.149
  26. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer. 2021 Nov 11.
    View in: PubMed
    Score: 0.061
  27. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021 11 08; 39(11):1531-1547.e10.
    View in: PubMed
    Score: 0.060
  28. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 05; 16(5):850-859.
    View in: PubMed
    Score: 0.057
  29. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021 01; 5:325-332.
    View in: PubMed
    Score: 0.057
  30. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clin Lung Cancer. 2021 05; 22(3):201-209.
    View in: PubMed
    Score: 0.057
  31. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
    View in: PubMed
    Score: 0.057
  32. Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Res. 2020 11 15; 80(22):5121-5133.
    View in: PubMed
    Score: 0.056
  33. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277.
    View in: PubMed
    Score: 0.054
  34. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019 09; 38(37):6399-6413.
    View in: PubMed
    Score: 0.052
  35. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity. Cell Rep. 2019 06 18; 27(12):3422-3432.e4.
    View in: PubMed
    Score: 0.051
  36. Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Res. 2019 07 15; 79(14):3776-3788.
    View in: PubMed
    Score: 0.051
  37. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2018 12; 8(12):1598-1613.
    View in: PubMed
    Score: 0.049
  38. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555.
    View in: PubMed
    Score: 0.049
  39. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.048
  40. Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Rep. 2017 Dec 12; 21(11):3298-3309.
    View in: PubMed
    Score: 0.046
  41. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res. 2018 01 01; 24(1):197-208.
    View in: PubMed
    Score: 0.046
  42. Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 11 14; 7:13513.
    View in: PubMed
    Score: 0.043
  43. End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. J Palliat Med. 2016 12; 19(12):1316-1319.
    View in: PubMed
    Score: 0.042
  44. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016 06 10; 7:11815.
    View in: PubMed
    Score: 0.042
  45. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016 Sep 15; 22(18):4585-93.
    View in: PubMed
    Score: 0.041
  46. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016 Mar; 22(3):262-9.
    View in: PubMed
    Score: 0.041
  47. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clin Cancer Res. 2015 Sep 01; 21(17):3924-33.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.